Skip to search formSkip to main contentSkip to account menu

efavirenz

Known as: (S)-6-chloro-4-(Cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one, (S)-6-chloro-4-Cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-benzo[D][1,3]oxazin-2-one, efavirenz, (S)-isomer 
A synthetic non-nucleoside reverse transcriptase (RT) inhibitor with antiviral activity. Efavirenz binds directly to the human immunodeficiency virus… 
National Institutes of Health

Related topics

Related topics

24 relations
Acquired Immunodeficiency SyndromeCYP2B6 protein, humanDrug AllergyEfavirenz:ACnc:Pt:Ser/Plas:Qn

Broader (7)

Antiviral AgentsBenzoxazinesCytochrome P-450 CYP2B6 InducersCytochrome P-450 CYP2C9 Inhibitors

Narrower (5)

AtriplaDMP 266L 743726Stocrin

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
Etravirine in treatment‐experienced, HIV‐1‐infected children and adolescents: 48‐week safety, efficacy and resistance analysis of the phase II PIANO study
PIANO (Paediatric study of Intelence As an NNRTI Option; TMC125‐C213; NCT00665847) assessed the safety/tolerability, antiviral… 
2012
2012
The effect of efavirenz versus nevirapine-containing regimens on immunologic, virologic and clinical outcomes in a prospective observational study
Objective:To compare regimens consisting of either efavirenz or nevirapine and two or more nucleoside reverse transcriptase… 
2012
2012
Pharmacokinetic Parameters of Once-Daily Rilpivirine following Administration of Efavirenz in Healthy Subjects
Background Rilpivirine and efavirenz share metabolic pathways (CYP3A), potentially leading to drug–drug interactions. We report… 
2011
2011
Efavirenz and Rifampicin in the South African Context: Is There a Need to Dose-Increase Efavirenz with Concurrent Rifampicin Therapy?
Background Increasing efavirenz (EFV) dose from 600 mg to 800 mg daily has been suggested with concomitant rifampicin (RFN), as… 
2011
2011
HIV/AIDS Patients Display Lower Relative Bioavailability of Efavirenz than Healthy Subjects
AbstractBackground: Pharmacokinetic studies of antiretroviral drugs are often conducted in adult healthy subjects, and the… 
2009
2009
Pharmacokinetics of Plasma Efavirenz and CYP2B6 Polymorphism in Southern Chinese
Cytochrome P450 2B6 (CYP2B6) is the main metabolizing pathway for efavirenz (EFV), the prescription of which is associated with… 
2009
2009
Pharmacokinetics and Safety of Etravirine Administered Once or Twice Daily After 2 Weeks Treatment With Efavirenz in Healthy Volunteers
Objective:To assess the pharmacokinetics of etravirine once and twice daily without and with a preceding efavirenz intake period… 
2009
2009
Stability- indicating HPLC method for the determination of efavirenz in bulk drug and in pharmaceutical dosage form
2� 0.999) was observed in the range of 0.05 - 0.15 mg/mL. The method was validated for accuracy and precision. The proposed… 
2008
2008
Prevalence of possible drug–drug interactions between antiretroviral agents in different age groups in a section of the private health care sector setting in South Africa
Background:  The chronic nature of human immunodeficiency virus (HIV) infection requires lifelong highly active antiretroviral… 
2004
2004
VHF cosite interference challenges and solutions for the United States Marine Corps' expeditionary fighting vehicle program
The United States Marine Corps' expeditionary fighting vehicle (EFV), currently under development, is a modern, highly… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)